SARS-CoV-2 Antibody Immunohistochemistry on a FFPE Infected Lung Tissue
|Intended Use||Analyte Specific Reagent|
|Summary and Explanation||
The Severe Acute Respiratory Syndrome 2 virus (SARS-CoV-2) is a betacoronavirus first isolated in Wuhan, China, in late 2019. The virus has a 29.8 kbp genome, containing instructions for the membrane, envelope, nucleocapsid, and spike glycoprotein. The spike proteins are cleaved by TMPRSS2 serine protease, and then bind to the ACE2 or CD147 to enter the cell. The Receptor Binding Domain of the Spike protein binds tighter to the ACE2 receptor than the similar spike protein of the SARS virus isolated in 2003.
The SARS-CoV-2 virus has been shown to infect the tracheal and lung epithelium, GI tract, and olfactory neuron, brain, bone marrow and possibly other organs. Cough, fever, and trouble breathing are the main symptoms, although GI distress, fatigue, and neurological distress are also common. Severe symptoms are more likely to appear in patients with advanced age and/or preexisting cardiovascular disease or diabetes. The virus has a 2-11 day incubation period and mortality rate around 2.5%. Severe symptoms include diffuse alveolar damage in the lungs, hyaline membrane formation, microthrombi in the lungs, heart, and brain, and extreme inflammation as “cytokine storms” that flood the body with cytokines (elevated 1L1, IL-6, IL-8, and TNFa among others) and immune cells (especially CD4+ and CD8+ T cells and CD68+ and CD163+ Macrophages).
|Antibody Type||Mouse Monoclonal||Clone||BSB-134|
|Localization||Cytoplasmic||Control||SARS-CoV-2 Infected Tissues|
|Presentation||SARS-CoV-2 antibody is a mouse monoclonal antibody derived from cell culture supernatant that is concentrated, dialyzed, filter sterilized and diluted in buffer pH 7.5, containing BSA and sodium azide as a preservative.|
|Note: For concentrated antibodies, please centrifuge prior to use to ensure recovery of all product.|